Retatrutide: what it is, and why you can't get it yet

Retatrutide is an investigational medication developed by Eli Lilly. Where semaglutide (the molecule in Ozempic and Wegovy) acts on a single gut-hormone receptor and tirzepatide (Mounjaro and Zepbound) acts on two, retatrutide is described as a triple agonist — it targets three pathways involved in appetite, metabolism and blood-sugar regulation.

That mechanism is why it has drawn so much attention. But a drug's mechanism and its approved, real-world use are very different things. Until trials conclude and regulators review the complete evidence, the responsible way to describe retatrutide is simple: promising in studies, and not available.

Early and mid-stage clinical trials of retatrutide have reported substantial average weight reduction among participants, which is what generated the headlines. Those are research findings from controlled studies in selected participants — not a promise of results for any individual, and not a basis for a treatment decision.

Clinical-trial results also come with caveats that marketing tends to strip away: they measure averages, they occur under close medical supervision, and the full safety picture only becomes clear as larger and longer studies complete. NorthDose won't translate trial numbers into anything that reads like advice. We'll report what regulators confirm, when they confirm it.

For retatrutide to reach Canadian patients, several things have to happen in order: late-stage trials must finish, the manufacturer must file for approval, and Health Canada must review the data and authorize it. Each step takes time, and none is guaranteed. Any specific date you see quoted today is speculation.

In the meantime, the approved GLP-1 options already on this site — from generic semaglutide to the newer tirzepatide products — are what Canadians can actually access. If you're weighing your choices now, those are the ones to discuss with a doctor.

Retatrutide isn't the only next-generation drug worth watching. Orforglipron is an investigational once-daily oral GLP-1 — also from Eli Lilly — currently in late-stage clinical trials. If retatrutide is interesting for its triple-agonist mechanism, orforglipron is interesting for its format: a small-molecule pill rather than an injection.

That format matters. Today's only oral GLP-1 in Canada, Rybelsus, is a peptide that needs careful handling to be absorbed. A small-molecule oral drug could, in principle, be simpler and cheaper to manufacture at scale — which is why orforglipron has drawn attention as a potential way to widen access. But "could" and "in principle" are doing real work in that sentence.

The same caveats apply as to retatrutide, and they're not fine print: orforglipron is not approved by Health Canada, is not for sale, and cannot be prescribed outside a clinical trial. Trial results are research findings, not a promise, and the full safety and efficacy picture only becomes clear as larger studies complete and regulators review them. We'll report what's confirmed, when it's confirmed.